CRP and nasopharyngeal carcinoma: This dynamic model identified primary refractory disease more accurately than single-marker kinetics.<h4>Conclusion</h4>The CRP-LDH-based IRI, both at baseline and during early treatment, is a practical tool for stratifying prognosis and dynamically monitoring response to PD-1 inhibitors in RM-NPC, which supports ongoing clinical evaluation.